İbrahim DUMAN, Serdar ARISAN, Palavan Narçin ÜNSAL, Damla BÜYÜKTUNÇER, Cem SÖNMEZ, Turhan ÇAŞKURLU

Apoptosis detection by TUNEL assay in BPH patients

Bu çalışmada benign prostat hiperplazisine sahip olan yaşlı erkeklerde apoptotik indeks hızındaki azalmayı göstermek amacı ile TUNEL yöntemi kullanılmıştır. Otuz sekiz prostat adenom kitlesi TUR-P sonrasında hastalarda alınmış ve hastaların 65 yaş veya üstü olmalarına göre gruplandınlmıştır. Apoptotik indeks, PSA seviyesi, IPSS ve yaşam kalitesi değerleri, her bir hasta için incelenmiştir. Hasta yaşı ve apoptoz arasında pozitif korelasyon saptanmıştır.

TUNEL yöntemi ile BPH hastalarında apoptoz tespiti

This study presents whether benign prostate growth in aging men correlates with a decrease in apoptotic rate, which were determined with terminal deoxnucleotidyl transferase mediated dUTP biotin nick end labelling (TUNEL). Thirty-eight prostate adenoma were taken from BPH patient who underwent TUR-P.The patient were devided two groups according to their age, 14 of them were under 65 years-old, the other 24 were over 65. Apoptotic indeces, PSA levels, IPSS-LQ, prostate tissue weight were evaluated in these two groups of patients. A significant higher apoptotic rate was observed in second group which contain prostatectomy speciment from patients over 65 age as compared under 65. There were positive correlation between the age and apoptotic rate in BPH patients.

PDF

___

Arends MJ and Wyllie AH. Apoptosis: Mechanisms and roles in pathology. International Rev Exp Pathol. 32: 223-227,1991.
Berry SJ, Coffey DS, Walsh PC, Ewing LL.The development of human benign prostatic hyperplasia with age. j Urol. 132: 474-479, 1984.
Berges RR, Vucanovic J, Epstein JI ,Walsh PC, Isaacs JT. Implication of cell cycle kinetic changes during the progression of human prostate cancer. Clin Cancer Res. 1: 473-479,1995.
Claus S, Berges R, Senge T, Schulze H. Cell kinetic in epithelium and stroma of benign prostatic hyperplasia. j Urol. 158: 217-221, 1997.
Colombel MF, Vacherot SG, Diez EF, Buttyan R, Chopin D. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia. British J of Urol. 82: 380-85, 1998.
Coffey DS, Berry SJ, Ewing LL. An overview of current concepts in the study of benign prostatic hyperplasia.In: Benign prostatic hyperplasia. Rodgers CH,Coffey DS,Cunha G,Grayback JT, Hinman F,Horton R (Eds). NIH publication National Institutes of Health Bethesda, 87-2881, 1999.
Deng F, Fangliu G, Tongli X. Proliferation and apoptosis status in benign prosraric hyperplasia. j Urol. 34: 15-18, 1996.
Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate. 2: 33-39, 1989.
Mc Neal JE.The prostate gland: Morphology and pathobiology. Monogr Urol. 4: 3-8, 1983.
Kyprianou N, Tu H. Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 27: 668-674,1996.
Siegfried C, Wrenger M, Senge T, Schulze H. Immunhistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res. 21: 305 308, 1993.
Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alphal-blockers on prostate cancer growth: a myth or an inviting reality? Prostate. 1: 91-100, 2004.
Walsh PC. Benign prostatic hyperplasia. In: Campell's Urology. Walsh PC, Gittes RF, Perlmutter AD, Stamey TA (Eds), 5th edn. Saunders, Philadelphia. 1248-1250, 1986.